Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Splicing01:32

RNA Splicing

56.5K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.5K
Alternative RNA Splicing02:18

Alternative RNA Splicing

21.3K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SAA1 Promotes Pro-inflammatory Macrophage-mediated Bone Invasion in Silent Corticotroph Adenomas.

Genomics, proteomics & bioinformatics·2026
Same author

Correction for Cheng et al., "Simultaneous expression of three G genotypes of VP7 proteins in a recombinant porcine rotavirus confers protective immunity against multiple rotavirus infections".

Journal of virology·2026
Same author

High-Performance Infrared Photodetectors Based on Graphene Nanoribbon Vertical Heterojunctions via Dissociated Double-Walled Carbon Nanotubes.

Nanomaterials (Basel, Switzerland)·2026
Same author

HELIX: a scalable model for predicting context-dependent regulation of RNA splicing and isoform usage.

Nature computational science·2026
Same author

Synergistic effects of konjac glucomannan and ultrasound treatment on inhibiting retrogradation and modifying structural properties of quinoa starch gels.

Food chemistry·2026
Same author

3D self-supporting PANI/CNT/CC composite cathode coupled with CNF/PAM dual network gel electrolyte for high specific capacity flexible zinc-ion battery.

BMC chemistry·2026

Related Experiment Video

Updated: Jul 18, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.0K

Targeting alternative splicing in cancer immunotherapy.

Nan Han1,2, Zhaoqi Liu1,2

  • 1Chinese Academy of Sciences Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing, China.

Frontiers in Cell and Developmental Biology
|August 28, 2023
PubMed
Summary

Alternative splicing (AS) generates cancer antigens and modulates immune responses, offering new avenues for cancer immunotherapy. Organoid technology aids in developing these splicing-based immunotherapies by preserving the tumor microenvironment.

Keywords:
alternative splicingcancerimmunotherapyorganoidprecision medicine

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.0K

Related Experiment Videos

Last Updated: Jul 18, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.0K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.6K
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.0K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Tumor immunotherapy faces challenges like limited antigens and patient response variability.
  • Alternative splicing (AS) is crucial for mRNA maturation and can expand cancer-specific antigens.
  • AS can modulate tumor immunogenicity, presenting a potential solution for immunotherapy limitations.

Purpose of the Study:

  • To summarize the critical roles of alternative splicing in cancer immunotherapy.
  • To highlight the benefits of organoid technology in developing splicing-based immunotherapies.
  • To discuss current challenges in studying AS-based immunotherapy.

Main Methods:

  • Literature review and synthesis of current research on alternative splicing and cancer immunotherapy.
  • Discussion of the application of organoid technology in this field.
  • Analysis of bioinformatics and biological technology limitations.

Main Results:

  • Alternative splicing serves as a source of neoantigens for immunotherapy.
  • AS can be modulated for immune-therapeutic targeting.
  • AS functions as a biomarker for guiding immunotherapy selection.
  • Organoids preserve the individual immune microenvironment, facilitating AS-based immunotherapy development.

Conclusions:

  • Alternative splicing presents a promising strategy to overcome current limitations in cancer immunotherapy.
  • Organoid technology offers a valuable platform for advancing splicing-based immunotherapies.
  • Further advancements in bioinformatics and biological technologies are needed to fully realize the potential of AS-based immunotherapy.